Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from EBOS Group Limited ( (NZ:EBO) ) is now available.
EBOS Group Limited has reported the lapse of 4,468 performance rights, refining the structure of its long-term incentive arrangements for management and employees. Following this change, the company now has 1,424,949 performance rights on issue, a modest adjustment that slightly alters potential future equity dilution for shareholders while signalling ongoing management of its incentive schemes.
The most recent analyst rating on (NZ:EBO) stock is a Buy with a N$28.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the NZ:EBO Stock Forecast page.
More about EBOS Group Limited
EBOS Group Limited is a healthcare and pharmaceutical distribution company listed on both the NZX and ASX. It is a major player in the Australasian market, supplying healthcare products and services across pharmacies, hospitals, and other medical channels.
YTD Price Performance: -22.27%
Average Trading Volume: 282,188
Technical Sentiment Signal: Sell
Current Market Cap: N$4.33B
For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.